The Role of Pyruvate Kinase M2 in Growth, Invasion and Drug Resistance in Human Urothelial Carcinoma
Study Details
Study Description
Brief Summary
Bladder urothelial carcinoma (UC) is a common malignancy and the incidence is increasing by years in Taiwan. Chemoresistance was inevitable in treatment of metastatic disease and lead to the ominous outcomes. To develop novel therapeutic strategies to overcome chemoresistance is imperative. Cancer cells uptake glucose at higher rates than normal tissue but use most of glucose for glycolysis even under normoxia condition, which is known as the Warburg effect. Pyruvate kinase (PK) catalyzes the last step in the process of glycolysis, and one of it isoform--PKM2 has been reported to be associated with tumor progression and some specific tissues and promotes the Warburg effect in cancer cells.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
|
Detailed Description
Regulation of PKM2 can be a novel target of cancer therapy. Meanwhile, PKM2 may play a critical role in the development of drug resistance and can be a promising target to overcome drug resistance.
In this study, our specific aims are as follows:
-
To prove the differentia expression levels of PKM2 in UC cells and drug-resistant UC cells, as well as in human UC tissues and drug-resistant UC tissues.
-
To examine the effect of PKM2 regulations（PKM2 siRNA and shikonin）on invasiveness and metastatic ability of UC cells and clarify the role of PKM2 in human UC cells.
-
To investigate the combinatory effect of PKM2 regulations（PKM2 siRNA and shikonin）and currently used chemotherapeutic agents (cisplatin，gemcitabine ,doxorubicin). Do PKM2 regulations enhance the cytotoxic effect of chemotherapy and overcome the chemoresistance？
-
To further prove the in vitro findings in the nude mice xenograft model。
Study Design
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| drug-resistant specimens com from drug-resistant bladder urothelial carcinoma patients. |
|
| normal specimens come from normal bladder urothelial carcinoma patients. |
|
| non-tumoral specimens come from non-tumoral patients. |
Outcome Measures
Primary Outcome Measures
- The IHC score [at the time of surgery]
the IHC scores are acquired by IHC staining and the comparisons between each specimen are determined by IHC scores.
Eligibility Criteria
Criteria
Inclusion Criteria:
- patients with age between 20-80 years old and had taken Radical Cystectomy or nephrectomy between 2008-2012
Exclusion Criteria:
- patients with age not located in the interval of 20-80 years old.
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | Department of Urology, National Taiwan University Hospital | Taipei | Taiwan | 10002 |
Sponsors and Collaborators
- National Taiwan University Hospital
Investigators
- Principal Investigator: Kuo-How Huang, M.D., Ph.D., Department of Urology, National Taiwan University Hospital, Taipei, Taiwan
Study Documents (Full-Text)
None provided.More Information
Publications
- Chen J, Xie J, Jiang Z, Wang B, Wang Y, Hu X. Shikonin and its analogs inhibit cancer cell glycolysis by targeting tumor pyruvate kinase-M2. Oncogene. 2011 Oct 20;30(42):4297-306. doi: 10.1038/onc.2011.137. Epub 2011 Apr 25.
- Christofk HR, Vander Heiden MG, Harris MH, Ramanathan A, Gerszten RE, Wei R, Fleming MD, Schreiber SL, Cantley LC. The M2 splice isoform of pyruvate kinase is important for cancer metabolism and tumour growth. Nature. 2008 Mar 13;452(7184):230-3. doi: 10.1038/nature06734.
- Vander Heiden MG, Cantley LC, Thompson CB. Understanding the Warburg effect: the metabolic requirements of cell proliferation. Science. 2009 May 22;324(5930):1029-33. doi: 10.1126/science.1160809. Review.
- Yang W, Lu Z. Regulation and function of pyruvate kinase M2 in cancer. Cancer Lett. 2013 Oct 10;339(2):153-8. doi: 10.1016/j.canlet.2013.06.008. Epub 2013 Jun 18. Review.
- 201308044RIN